Journal
ALZHEIMERS & DEMENTIA
Volume 12, Issue 6, Pages 645-653Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.02.006
Keywords
Azheimer's disease; Biomarkers; Crowdsource; Big data; Bioinformatics; Cognitive decline; Imaging; Genetics
Categories
Funding
- National Institutes of Health [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- NIH grants [P30 AG010129, K01 AG030514, P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152]
- Rush Alzheimer's Disease Center
- Rush University Medical Center
- Illinois Department of Public Health
- Translational Genomics Research Institute
- EFPIA companies
- EU under the FP6 programme
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica, Inc.
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- GE Healthcare
- Innogenetics, N.V.
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Synarc Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- SMEs
- McGill University
- MSSM
- UCSF
- Goteborg University
- EMA
- University of Washington
- UCLA
- BrightFocus Foundation
- NIA
- Alzheimer's Research UK
- European Medicines Agency
- Global CEO Initiative on Alzheimer's Disease
- Pfizer, Inc
- Ray and Dagmar Dolby Family Fund
- Rosenberg Alzheimer's Project
- Sanofi S.A
- Takeda Pharmaceutical Company Ltd
- USA gainst Alzheimer's
Ask authors/readers for more resources
Identifying accurate biomarkers of cognitive decline is essential for advancing early diagnosis and prevention therapies in Alzheimer's disease. The Alzheimer's disease DREAM Challenge was designed as a computational crowdsourced project to benchmark the current state-of-the-art in predicting cognitive outcomes in Alzheimer's disease based on high dimensional, publicly available genetic and structural imaging data. This meta-analysis failed to identify a meaningful predictor developed from either data modality, suggesting that alternate approaches should be considered for prediction of cognitive performance. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
